Fulcrum Therapeutics (FULC) Receivables (2020 - 2024)

Fulcrum Therapeutics (FULC) has reported Receivables for 5 consecutive years, with $2.1 million the latest figure, recorded in Q4 2024.

• In Q4 2024, Receivables rose 290.32% year-over-year to $2.1 million; the TTM figure through Dec 2024 stood at $2.1 million (up 290.32% YoY), while the FY2024 annual figure was $2.1 million, up 290.32% from the prior year.
• Receivables climbed to $2.1 million in Q4 2024 per FULC's latest filing, from $537000.0 in the prior quarter.
• Across five years, Receivables topped out at $5.0 million in Q4 2021 and bottomed at $229000.0 in Q4 2022.
• Historically, Receivables has averaged $1.4 million across 5 years, with a median of $802500.0 in 2022.
• Annual changes were most pronounced in 2022 — Receivables sank 95.42% — and 2024, when it jumped 290.32%.
• Fulcrum Therapeutics' Receivables stood at $2.5 million in 2020, then surged by 97.55% to $5.0 million in 2021, then tumbled by 95.42% to $229000.0 in 2022, then jumped by 134.5% to $537000.0 in 2023, then surged by 290.32% to $2.1 million in 2024.
• Business Quant data shows FULC's Receivables at $2.1 million in Q4 2024, $537000.0 in Q4 2023, and $580000.0 in Q3 2023.